Serveur d'exploration sur la recherche en informatique en Lorraine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt

Identifieur interne : 00EF25 ( Main/Exploration ); précédent : 00EF24; suivant : 00EF26

Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt

Auteurs : M. Kabiri [Iran] ; E. Basiri [Iran] ; D. Kadivar [Iran]

Source :

RBID : ISTEX:28D47B5BBB9535AC85389454E8E79C91F70F1ADE

English descriptors

Abstract

In mice treated with sodium aurothiomalate (myocrisin), prior to infection with Coxsackievirus B3, 90% of the animals died by the 11 th day postinfection (p.i.) A mortality of 10% was noted in mice receiving myocrisin only, and no deaths occurred in animals infected with virus alone. The highest amount of virus was recovered from the pancreas of myocrisin‐treated mice on day 3 p.i. This was over 500‐fold higher than the virus titer found in the pancreas of mice infected with virus only. Generally the titer of virus present in different organs was higher at every point in drug‐treated animals as compared to intact mice infected with the virus. A high and persistent viremia was present in myocrisin‐treated mice; in contrast a low viremia followed by virus clearance from the blood was observed in intact mice infected with the virus. The antibody response was studied in intact and myocrisin‐treated mice infected with the virus. In both groups, no neutralizing antibodies were detected on days 1, 2, and 3 p.i. On day 7 after infection, the titers of antibodies were 1:16 and 1:12 in intact and myocrisin‐treated mice, respectively. Administration of hyperimmune anti‐Coxsackievirus B3 serum 6 hours after infection protrected the myocrisin‐treated group of mice against lethal disease. The results of these studies suggest that (1) antibodies alone may not be sufficient to limit the spread and persistence of virus in natural infections and (2) in the absence of any apparent histopathological differences the increased multiplication of Coxsackievirus B3 could be the cause of death in myocrisintreated mice.

Url:
DOI: 10.1002/jmv.1890030206


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt</title>
<author>
<name sortKey="Kabiri, M" sort="Kabiri, M" uniqKey="Kabiri M" first="M." last="Kabiri">M. Kabiri</name>
</author>
<author>
<name sortKey="Basiri, E" sort="Basiri, E" uniqKey="Basiri E" first="E." last="Basiri">E. Basiri</name>
</author>
<author>
<name sortKey="Kadivar, D" sort="Kadivar, D" uniqKey="Kadivar D" first="D." last="Kadivar">D. Kadivar</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:28D47B5BBB9535AC85389454E8E79C91F70F1ADE</idno>
<date when="1978" year="1978">1978</date>
<idno type="doi">10.1002/jmv.1890030206</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-G55T4WX5-7/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000946</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000946</idno>
<idno type="wicri:Area/Istex/Curation">000941</idno>
<idno type="wicri:Area/Istex/Checkpoint">003A43</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">003A43</idno>
<idno type="wicri:doubleKey">0146-6615:1978:Kabiri M:potentiation:of:coxsackievirus</idno>
<idno type="wicri:Area/Main/Merge">00F817</idno>
<idno type="wicri:Area/Main/Curation">00EF25</idno>
<idno type="wicri:Area/Main/Exploration">00EF25</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt</title>
<author>
<name sortKey="Kabiri, M" sort="Kabiri, M" uniqKey="Kabiri M" first="M." last="Kabiri">M. Kabiri</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Departments of Microbiology and Pathology, Medical School, Pahlavi University, Shiraz</wicri:regionArea>
<wicri:noRegion>Shiraz</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr" wicri:curation="lc">Iran</country>
<wicri:regionArea>Correspondence address: Dept of Microbiology, Medical School, Pahlavi Univ, Shiraz</wicri:regionArea>
<wicri:noRegion>Shiraz</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Basiri, E" sort="Basiri, E" uniqKey="Basiri E" first="E." last="Basiri">E. Basiri</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Departments of Microbiology and Pathology, Medical School, Pahlavi University, Shiraz</wicri:regionArea>
<wicri:noRegion>Shiraz</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Kadivar, D" sort="Kadivar, D" uniqKey="Kadivar D" first="D." last="Kadivar">D. Kadivar</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Iran</country>
<wicri:regionArea>Departments of Microbiology and Pathology, Medical School, Pahlavi University, Shiraz</wicri:regionArea>
<wicri:noRegion>Shiraz</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Journal of Medical Virology</title>
<title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title>
<idno type="ISSN">0146-6615</idno>
<idno type="eISSN">1096-9071</idno>
<imprint>
<biblScope unit="vol">3</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="125">125</biblScope>
<biblScope unit="page" to="136">136</biblScope>
<biblScope unit="page-count">12</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1978">1978</date>
</imprint>
<idno type="ISSN">0146-6615</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0146-6615</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Acinar cells</term>
<term>Adult animals</term>
<term>Adult mice</term>
<term>Allison</term>
<term>American journal</term>
<term>Antibody production</term>
<term>Antibody response</term>
<term>Avirulent strains</term>
<term>Basiri</term>
<term>Cell cultures</term>
<term>Coxsackievirus</term>
<term>Coxsackievirus infection</term>
<term>Different days</term>
<term>Different organs</term>
<term>Fatal disease</term>
<term>First group</term>
<term>General virology</term>
<term>Gold salt</term>
<term>Gold salts</term>
<term>Hyperimmune serum</term>
<term>Infection</term>
<term>Intact mice</term>
<term>Intraperitoneal administration</term>
<term>Kabiri</term>
<term>Kadivar</term>
<term>Lethal disease</term>
<term>Lethal infection</term>
<term>Medical school</term>
<term>Mesenteric lymph nodes</term>
<term>Mouse</term>
<term>Myocrisin</term>
<term>Myocrisintreated mice</term>
<term>Natural infection</term>
<term>Natural infections</term>
<term>Necrotic changes</term>
<term>Neutralizing</term>
<term>Neutralizing antibodies</term>
<term>Neutralizing antibody</term>
<term>Newborn mice</term>
<term>Normal mice</term>
<term>Normal mouse serum</term>
<term>Original magnification</term>
<term>Pancreas</term>
<term>Peritoneal exudate cells</term>
<term>Persistent viremia</term>
<term>Protective effect</term>
<term>Razi institute</term>
<term>Rheumatoid arthritis</term>
<term>Second group</term>
<term>Semliki forest virus</term>
<term>Semlikie forest virus</term>
<term>Sodium aurothiomalate</term>
<term>Spleen</term>
<term>Streptomycin sulphate</term>
<term>Suckling mice</term>
<term>Susceptibility</term>
<term>Titer</term>
<term>Various organs</term>
<term>Viral</term>
<term>Viral concentration</term>
<term>Viral infection</term>
<term>Viral infections</term>
<term>Viral titer</term>
<term>Viremia</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus concentration</term>
<term>Virus titer</term>
<term>Virus titers</term>
<term>Zisman</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">In mice treated with sodium aurothiomalate (myocrisin), prior to infection with Coxsackievirus B3, 90% of the animals died by the 11 th day postinfection (p.i.) A mortality of 10% was noted in mice receiving myocrisin only, and no deaths occurred in animals infected with virus alone. The highest amount of virus was recovered from the pancreas of myocrisin‐treated mice on day 3 p.i. This was over 500‐fold higher than the virus titer found in the pancreas of mice infected with virus only. Generally the titer of virus present in different organs was higher at every point in drug‐treated animals as compared to intact mice infected with the virus. A high and persistent viremia was present in myocrisin‐treated mice; in contrast a low viremia followed by virus clearance from the blood was observed in intact mice infected with the virus. The antibody response was studied in intact and myocrisin‐treated mice infected with the virus. In both groups, no neutralizing antibodies were detected on days 1, 2, and 3 p.i. On day 7 after infection, the titers of antibodies were 1:16 and 1:12 in intact and myocrisin‐treated mice, respectively. Administration of hyperimmune anti‐Coxsackievirus B3 serum 6 hours after infection protrected the myocrisin‐treated group of mice against lethal disease. The results of these studies suggest that (1) antibodies alone may not be sufficient to limit the spread and persistence of virus in natural infections and (2) in the absence of any apparent histopathological differences the increased multiplication of Coxsackievirus B3 could be the cause of death in myocrisintreated mice.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Iran</li>
</country>
</list>
<tree>
<country name="Iran">
<noRegion>
<name sortKey="Kabiri, M" sort="Kabiri, M" uniqKey="Kabiri M" first="M." last="Kabiri">M. Kabiri</name>
</noRegion>
<name sortKey="Basiri, E" sort="Basiri, E" uniqKey="Basiri E" first="E." last="Basiri">E. Basiri</name>
<name sortKey="Kabiri, M" sort="Kabiri, M" uniqKey="Kabiri M" first="M." last="Kabiri">M. Kabiri</name>
<name sortKey="Kadivar, D" sort="Kadivar, D" uniqKey="Kadivar D" first="D." last="Kadivar">D. Kadivar</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00EF25 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00EF25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Lorraine
   |area=    InforLorV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:28D47B5BBB9535AC85389454E8E79C91F70F1ADE
   |texte=   Potentiation of coxsackievirus B3 infection in adult mice pretreated with a gold salt
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Jun 10 21:56:28 2019. Site generation: Fri Feb 25 15:29:27 2022